A new independent 537 page research with title ‘Age Related Macular Degeneration – Pipeline Review, H2 2017’ guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions and important players/vendors such as 3SBio Inc, Abzena Plc, Achillion Pharmaceuticals Inc, Aciont, etc… With n-number of tables and figures examining the Age Related Macular Degeneration, the research gives you a visual, one-stop breakdown of the leading products, submarkets and market leader’s market revenue forecasts as well as analysis to 2022
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/871954-age-related-macular-degeneration-pipeline-review-1
Age Related Macular Degeneration – Pipeline Review, H2 2017
The latest Pharmaceutical and Healthcare disease pipeline guide Age Related Macular Degeneration – Pipeline Review, H2 2017, provides an overview of the Age Related Macular Degeneration (Ophthalmology) pipeline landscape.
Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in depreciation of the macula that may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity etc. Symptoms include development of blind spot and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy and medication such as anti-angiogenic drugs.
The Pharmaceutical and Healthcare latest pipeline guide Age Related Macular Degeneration – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Age Related Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 27, 18, 4, 135, 29 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 16 and 2 molecules, respectively.
Age Related Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration (Ophthalmology).
– The pipeline guide reviews pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Age Related Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Age Related Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Age Related Macular Degeneration (Ophthalmology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Age Related Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
3SBio Inc, Abzena Plc, Achillion Pharmaceuticals Inc, Aciont Inc, Acucela Inc, AdAlta Ltd, Adverum Biotechnologies Inc, Aerie Pharmaceuticals Inc, Aerpio Therapeutics Inc, Alimera Sciences Inc, Alkeus Pharmaceuticals Inc, Allergan Plc, Allgenesis Biotherapeutics Inc, Allinky Biopharma, Alteogen Inc, Amarna Therapeutics BV, Apellis Pharmaceuticals Inc, Apexigen Inc, Applied Genetic Technologies Corp, Ascentage Pharma Group Corp Ltd, Astellas Pharma Inc, Benitec Biopharma Ltd, Biokine Therapeutics Ltd, BioMAS Ltd, Biomics Biotechnologies Co Ltd, Biophytis SAS, Caladrius Biosciences Inc, Catalyst Biosciences Inc, Cell Cure Neurosciences Ltd, Cell Medica Ltd, Charlesson LLC, Chong Kun Dang Pharmaceutical Corp, CJ HealthCare Corp, Clanotech AB, Coherus BioSciences Inc, Colby Pharmaceutical Co, Crinetics Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Diffusion Pharmaceuticals Inc, Dong-A Socio Holdings Co Ltd, Eleven Biotherapeutics Inc, Elsalys Biotech SAS, Enzene Biosciences Ltd, Exonate Ltd, EyeGate Pharmaceuticals Inc, Eyevensys SAS, F. Hoffmann-La Roche Ltd, FirstString Research Inc, Foamix Pharmaceuticals Ltd, Formycon AG, Gene Techno Science Co Ltd, Genentech Inc, GenSight Biologics SA, Graybug Vision Inc, HanAll Biopharma Co Ltd, Huabo Biopharm Co Ltd, Icon Bioscience Inc, Iconic Therapeutics Inc, Ildong Pharmaceutical Co Ltd, Inception Sciences Inc, Innovent Biologics Inc, Intellect Neurosciences Inc, Ionis Pharmaceuticals Inc, Jeil Pharmaceutical Co Ltd, Johnson & Johnson, Just Biotherapeutics Inc, Kala Pharmaceuticals Inc, Kodiak Sciences Inc, Lead Discovery Center GmbH, LeadArtis SL, Lee’s Pharmaceutical Holdings Ltd, Lupin Ltd, M’s Science Corp, Mabion SA, MacuCLEAR Inc, Mitotech SA, Mitsubishi Tanabe Pharma Corp, Mor Research Application Ltd, Navya Biologicals Pvt Ltd, Neovacs SA, Novartis AG, NovelMed Therapeutics Inc, Ocular Therapeutix Inc, Ohr Pharmaceutical Inc, Ophthotech Corp, Oxford BioMedica Plc, Oxular Ltd, PanOptica Inc, Paras Biopharmaceuticals Finland Oy, Pfenex Inc, Pfizer Inc, PlantForm Corp, Promedior Inc, pSivida Corp, Ra Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, RegenxBio Inc, Ribomic Inc, RXi Pharmaceuticals Corp, SanBio Inc, SciFluor Life Sciences LLC, Senju Pharmaceutical Co Ltd, Stealth BioTherapeutics Inc, Sumitomo Dainippon Pharma Co Ltd, Sun Pharma Advanced Research Company Ltd, Sylentis SAU, TRACON Pharmaceuticals Inc, Tyrogenex Inc, Wellstat Ophthalmics Corp, Xbrane Biopharma AB
Request a sample report @ https://www.htfmarketreport.com/sample-report/871954-age-related-macular-degeneration-pipeline-review-1
Table of Contents
Table of Contents 2
Age Related Macular Degeneration – Overview 7
Age Related Macular Degeneration – Therapeutics Development 8
Age Related Macular Degeneration – Therapeutics Assessment 37
Age Related Macular Degeneration – Companies Involved in Therapeutics Development 51
Age Related Macular Degeneration – Drug Profiles 101
Age Related Macular Degeneration – Dormant Projects 487
Age Related Macular Degeneration – Discontinued Products 499
Age Related Macular Degeneration – Product Development Milestones 501
Appendix 511List of Tables
Number of Products under Development for Age Related Macular Degeneration, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage an
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/871954-age-related-macular-degeneration-pipeline-review-1
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
Place a Purchase Order for this Market Study (Single User License) at: https://www.htfmarketreport.com/buy-now?format=1&report=871954
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218